By Kelley Herring
For decades you’ve heard the message from doctors, pharmacists, drug ads – and probably a few well-meaning friends and relatives – that it is important to “lower your cholesterol” to reduce your risk of heart disease.
And of course, the most common suggestion from mainstream medicine is to simply take a statin drug. “Don’t worry,” you’re told. “These drugs are safe and effective.”
Today, you’ll discover that while these drugs ARE effective (more on that in a moment) – they are certainly not safe. In fact, it seems we can now add the dreaded neurological condition Parkinson’s to the list of potential “side effects” of statin drugs.
But first, let’s cover a few of…
The Stats on Statins
Currently more than 35 million people take statin drugs to lower their cholesterol. And the use of these drugs has increased 80% in the last 15 years. The National Health & Nutrition Examination Survey (NHANES) estimates that 22% of Americans 45 years and older take a statin drug.
And with more than 100 million Americans diagnosed with “high cholesterol”, it’s clear that statins are HUGE business for Big Pharma. In fact, the sales of Lipitor alone are more than $95 billion dollars since its market debut!
It’s no wonder drug companies have launched massive fear campaigns about cholesterol. There are unimaginable sums of money to be made. The question is: Should you believe them?
Statins ARE Effective… but Why Would You Want to Take them?
The bottom line is that statin drugs work VERY well to lower cholesterol numbers. And if that was the only way to grade their effectiveness, then they would pass with flying colors. Unfortunately, there’s never been any proof that this actually reduces your risk of dying from heart disease.
In this case, you can take the drug company’s word for it, because the (really) fine print on the ads for Lipitor actually state: “Lipitor has not been shown to prevent heart disease or heart attacks.”
But more importantly, we should consider whether it is appropriate to demonize “cholesterol” in the first place…
Cholesterol: A Few Benefits of this Maligned Substance
Cholesterol is an extremely versatile compound that is vital to the human body (it should also be stated that natural levels differ greatly among individuals, so there is no “standard” healthy levels for this substance).
The importance of cholesterol is clear, when you consider its primary functions in the body:
1. Used to manufacture hormones (including sex hormones), which control a myriad of bodily functions.
2. Helps the liver produce bile acids, essential for digestion of fats and ridding the body of waste.
3. Helps to interlock “lipid molecules” which are the basis of all cell membranes.
4. Essential to the “myelin sheath” around nerves, which aids the passage of electrical impulses.
Given the critical nature of these functions, it doesn’t make much sense to artificially lower this compound with the use of chemicals. And we should not be surprised that doing so can result in serious unintended consequences!
Of course, the drug industry refers to these unintended consequences as “side effects”. And if you’ve been following natural and alternative health for a while, you’re probably familiar with a few, including:
Depletion of vital Coenzyme Q10 (CoQ10)
Excruciating muscle pain (statin-induced myopathy)
Increased A1C levels (a measure of poor blood sugar control)
Studies have also shown that cancer diagnoses are significantly higher among those on statins.
Now, there’s another potential “side effect” we can add to the list: Parkinson’s disease.
Lower Cholesterol, Higher Parkinson’s Risk
Researchers at Penn State evaluated whether statin drugs were protective against Parkinson’s… or if these drugs could accelerate its development.
The study, published in the journal Movement Disorders, analyzed data of insurance claims for more than 50 million people. Of those, nearly 22,000 had Parkinson’s disease (with 2,322 classified as “newly diagnosed”). They also evaluated which patients had been taking a statin and for how long before Parkinson’s symptoms appeared.
The researchers discovered that prior statin use was associated with higher risk of Parkinson’s. And the risk was more pronounced during the start of the drug use. Neurology professor and one of the authors of the study, Dr. Xuemei Huang said:
“Statin use was associated with higher, not lower, Parkinson’s disease risk, and the association was more noticeable for lipophilic statins, an observation inconsistent with the current hypothesis that these statins protect nerve cells. In addition, this association was most robust for use of statins less than two and a half years, suggesting that statins may facilitate the onset of Parkinson’s disease.”
With the results of this large-scale study showing that artificially lowering cholesterol can induce Parkinson’s, it seems intuitive that higher cholesterol levels might actually protect against the disease.
And that’s exactly what researchers at Tel Aviv University found…
Higher Total and LDL Cholesterol May Protect Against Parkinson’s
To explore the association between high cholesterol levels and Parkinson’s risk, researchers reviewed the clinical records of more than a quarter million patient records, collected from medical databases in Israel.
The study included patients aged 40 – 79, who did not receive statins. During the study period, 746 patients were diagnosed with Parkinson’s disease.
At the beginning of the study, total cholesterol and LDL-C levels were similar among men and women (and slightly higher than what is considered “optimal” by conventional standards). Roughly one-third of the participants had LDL-C levels above 140 mg/dL – the level at which statin therapy is typically recommended.
Researchers found that total cholesterol levels higher than 180 mg/dL and LDL-C higher than 110 mg/dL were associated with a reduced risk of Parkinson’s disease in statin-free middle-age men and elderly women. For men ages 50 to 69, higher total cholesterol levels were associated with an 18-29% reduced risk of Parkinson’s. High LDL-C levels were also linked to a 20-28% reduced risk.
In women ages 70 to 74, researchers found a similar protective association (with lower impact). Higher total cholesterol levels were linked to a reduced risk of up to 7%, and high LDL-C levels correlated with a 2-12% reduced risk of Parkinson’s.
The study concluded:
“Higher levels of total and low‐density lipoprotein cholesterol among men over time indicated a decreased PD risk. The potential role of cholesterol in disease protection warrants further investigation.”
And as to that last statement, we couldn’t agree more!
How Does Cholesterol Protect Against Parkinson’s?
The brain is the organ with the highest concentrations of cholesterol (and we’ve already noted that cholesterol is required to manufacture steroid hormones).
But how can cholesterol help guard against Parkinson’s?
The answer may lie in its unique (and surprising!) ability to guard against free radicals. You see, while we need oxygen to survive, it also generates reactive oxygen species (free radicals), which can damage cells.
A study published in Clinical & Experimental Pharmacology and Physiology found that people with higher cholesterol levels had lower levels of tissue oxygen saturation, which translates to a reduced oxidative stress load. This would clearly be protective against Parkinson’s disease (among other things).
And it may also explain why people living at high altitudes (and therefore lower oxygen saturation) have lower risk of cardiovascular diseases and certain cancers.
How to Optimize Your Cholesterol Levels for Better Health
These ancestral “functional” foods are excellent sources of vital saturated fats that help your body build healthy cholesterol.
Let me quantify “healthy cholesterol” a bit…
Healthy cholesterol is made of large, fluffy “beach ball” particles. Because of their large size, this type of cholesterol particle is not linked with increased risk for cardiovascular disease. On the contrary – people with large cholesterol particles are at even lower risk of heart disease than people who have low total cholesterol!
Along with large particles of cholesterol, you also want your cholesterol to be protected from oxidation (damage by free radicals). Your cholesterol can be oxidized primarily by consuming excess sugar and omega-6 fats – like those found in seed and industrial oils (canola, corn, soy, etc).
To prevent Parkinson’s disease, follow the wisdom of our ancestors:
Rely on sound nutrition, including healthy ancestral fats and omegas in the right ratios
Keep your blood sugar stable with a low glycemic impact, low carb or keto diet
Avoid exposure to chemicals of all kinds – especially pesticides
Drink clean water, get sound sleep and regular sunshine, and move your body
And beware of pharmaceuticals, which often have irreversible, unintended consequences!
Kelley Herring is the author of the brand new book Keto Breads – which includes more information you need to know about why it is so important to avoid wheat and grains in your diet, plus how to use healthy replacements for these foods to create all the breads you love… without the gluten, carbs and health-harming effects. Click here to learn more about Keto Breads…
- Naci H, et al. (2013). Comparative tolerability and harms of individual statins. circoutcomes.ahajournals.org/content/6/4/390.long
- FDA drug safety communication: Important safety label changes to cholesterol-lowering statin drugs. (2016). fda.gov/Drugs/DrugSafety/ucm293101.htm
- Cardiovascular Business: “AHA 2016: Statin use among adults increases 80 percent from 2002 to 2013” November 14, 2016
- Shepard, J. et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet. 2002 Nov 23:360(9346):1623-30.
- Sacks FM, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. New England Journal of Medicine. 1996 Oct 3;335(14):1001-9.
- Alexander Rossi, Kristin Berger, Honglei Chen, Douglas Leslie, Richard B. Mailman, Xuemei Huang. Projection of the prevalence of Parkinson’s disease in the coming decades: Revisited. Movement Disorders, 2017
- Rozani, V. , Gurevich, T. , Giladi, N. , El‐Ad, B. , Tsamir, J. , Hemo, B. and Peretz, C. (2018), Higher serum cholesterol and decreased Parkinson’s disease risk: A statin‐free cohort study. Mov Disord., 33: 1298-1305.
- Singh A, Kukreti R, Saso L, Kukreti S. Oxidative Stress: A Key Modulator in Neurodegenerative Diseases. Molecules. 2019;24(8):1583. Published 2019 Apr 22. doi:10.3390/molecules24081583
- Buchwald H1, O’Dea TJ, Menchaca HJ, Michalek VN, Rohde TD.Effect of plasma cholesterol on red blood cell oxygen transport.Clin Exp Pharmacol Physiol. 2000 Dec;27(12):951-5.
- Davidson MH1, Ballantyne CM, Jacobson TA, Bittner VA, Braun LT, Brown AS, Brown WV, Cromwell WC, Goldberg RB, McKenney JM, Remaley AT, Sniderman AD, Toth PP, Tsimikas S, Ziajka PE, Maki KC, Dicklin MR.Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists.J Clin Lipidol. 2011 Sep-Oct;5(5):338-67. doi: 10.1016/j.jacl.2011.07.005.
- Kresser, Chris. The Diet Heart Myth Everyone Should Know: https://kresserinstitute.com/diet-heart-myth-everyone-know-ldl-particle-number/
- Kaliora AC1, Gioxari A2, Kalafati IP1, Diolintzi A1, Kokkinos A2, Dedoussis GV1. The Effectiveness of Mediterranean Diet in Nonalcoholic Fatty Liver Disease Clinical Course: An Intervention Study. J Med Food. 2019 Jul;22(7):729-740. doi: 10.1089/jmf.2018.0020.
- Gradinaru D1, Borsa C2, Ionescu C2, Prada GI3. Oxidized LDL and NO synthesis–Biomarkers of endothelial dysfunction and ageing. Mech Ageing Dev. 2015 Nov;151:101-13. doi: 10.1016/j.mad.2015.03.003. Epub 2015 Mar 21.
- Kita T1, Kume N, Minami M, Hayashida K, Murayama T, Sano H, Moriwaki H, Kataoka H, Nishi E, Horiuchi H, Arai H, Yokode M. Role of oxidized LDL in atherosclerosis. Ann N Y Acad Sci. 2001 Dec;947:199-205; discussion 205-6.
- Morgan G. Stykel, Kayla Humphries, Mathew P. Kirby, Chris Czaniecki, Tinya Wang, Tammy Ryan, Vladimir Bamm, Scott D. Ryan. Nitration of microtubules blocks axonal mitochondrial transport in a human pluripotent stem cell model of Parkinson’s disease. The FASEB Journal, 2018; fj.201700759RR DOI: